Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

Mild Clostridium difficile infection (CDI ... clinical deterioration and place on therapy immediately if this occurs. Treatment for an initial episode and a first recurrence of CDI: If oral ...

Purpose: Current and future treatment modalities for Clostridium difficile-associated disease (CDAD) are reviewed. Conclusion: CDAD is a major concern for health care systems and clinicians.

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Among 547 episodes of C difficile infection documented in cancer patients in Australia and Spain, 50% were severe, and the 90 ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Highlights:New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...

Although more evidence is needed, probiotics may help your immune system by creating and maintaining a healthy gut microbiome ...

In a counterintuitive move, bacteria are known to produce self-destructive toxins. However, they also make antitoxins, and ...

Explore Summit Therapeutics' stock performance and financial health amid ivonescimab concerns, and learn how to strategically ...